The latest data point for LLY's net income in Q4'25 shows a robust $6.64B, marking a significant increase from the previous quarter's $5.58B and reflecting strong year-end performance amid favorable market conditions. Over the period from Q1'23 to Q4'25, net income exhibited volatile but predominantly upward trends, starting with $1.34B in Q1'23, dipping to a loss of -$57M in Q3'23, and then surging to peaks of $5.66B in Q2'25 and $6.64B in Q4'25, driven by YoY growth rates that ranged from -104% in Q3'23 to an exceptional 1,790% in Q3'24. Key inflection points include the Q3'23 downturn followed by consistent recovery, with average quarterly growth accelerating post-2024, underscoring improved operational efficiency and revenue streams in the pharmaceutical sector. Overall, the bar chart highlights a resilient trajectory, with YoY line overlays confirming sustained positive momentum in recent fiscal years.